Pili Ferrer

Pili Ferrer

Auto-generated profile, based on publicly available information

Pili Ferrer

Foundation Catalan Institute of Pharmacology, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2009 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
PFPili Ferrer
Pili Ferrer
IRIan Roberts
Ian Roberts
ESEmma Sydenham
Emma Sydenham
KBKaren Blackhall
Karen Blackhall
HSHaleema Shakur
Haleema Shakur
Background: Post partum haemorrhage is a leading cause of maternal death worldwide. It also contributes to maternal morbidity as women may require a hysterectomy to control bleeding, or may require a blood transfusion, which can transmit viral infections. Anti-fibrinolytic agents have been proposed as a treatment for post partum haemorrhage. We conducted a systematic review to assess the effectiveness and safety of anti-fibrinolytic agents in post partum bleeding. Methods: All randomised controlled trials of anti-fibrinolytic agents given for bleeding during the postpartum period were included in this review. We searched Medline, PubMed, EMBASE, Cochrane Central Register of Controlled trials, Web of Science, metaRegister of controlled trials, LILACS, Reproductive Health Library, African healthline, POPLINE, MedCarib, CINAHL, Clinicaltrials.gov and the reference lists of eligible trials. Two authors extracted data. Methodological quality was assessed by evaluating allocation concealment. The primary outcome was maternal mortality. Secondary outcomes were blood loss, blood transfusion, hysterectomy, mean haemoglobin concentration, thrombo-embolic events and other adverse effects. Results: We identified three randomised controlled trials involving 461 participants. The trials compared tranexamic acid with no treatment and reported blood loss after delivery. In all three trials, allocation concealment was either inadequate or unclear. The administration of tranexamic acid was associated with a reduction in blood loss of 92 millilitres (95%CI 76 to 109). The most frequently reported adverse effect of tranexamic acid was nausea, although the increase was easily compatible with the play of chance (RR 4.63, 95%CI 0.23 to 95.14). Conclusion: Tranexamic acid may reduce blood loss in post partum haemorrhage. However, the quality of the currently available evidence is poor. Adequately powered, high quality randomised controlled trials are needed.

3 January 2014 in Neuroepidemiology
Verified
Journal Article
Open access
PDF file
PFPili Ferrer
Pili Ferrer
EBElena Ballarín
Elena Ballarín
MSMònica Sabaté
Mònica Sabaté
XVXavier Vidal
Xavier Vidal
MRMarietta Rottenkolber
Marietta Rottenkolber
LILuisa Ibáñez
Luisa Ibáñez
Background: Since the FDA (Food and Drug Administration) report on antiepileptic drugs (AEDs) and suicide risk was released (2008), several studies have been published on this controversial relationship. This systematic review (SR) gives an updated approach to this health issue. Summary: We searched 6 databases. We ultimately included 11 publications: 4 cohort studies, 1 case-crossover study, 2 community case-control studies, and 4 SRs. Overall, 1 SR described studies already included; 3 studies reported a 2- to 4-fold overall increase in risk; 1 study reported an increased risk of suicide among epilepsy patients on AEDs with high risk of depression; 1study showed a protective effect among epilepsy patients; 2 studies were conducted with patients with bipolar disorder (1 showed a protective effect, whereas the other showed a 3-fold increase in risk of suicide), and the other 3 studies reported results for single AEDs. Several biases affected the published results. Key Messages: There is no clear evidence of an association between the use of AEDs and an increased risk of suicide because of the heterogeneity in the studies at the clinical and methodological level. A future study should cover all indications for use, retrieve information from a healthcare database, and include a defined set of covariates to avoid bias.

1 June 2017 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
JFJean-Luc Faillie
Jean-Luc Faillie
PFPili Ferrer
Pili Ferrer
AGAmandine Gouverneur
Amandine Gouverneur
DDDamien Driot
Damien Driot
SBShoma Berkemeyer
Shoma Berkemeyer
LILuisa Ibáñez
Luisa Ibáñez

30 May 2014 in International Journal of Public Health
Verified
Journal Article
Closed access
PDF file
PFPili Ferrer
Pili Ferrer
EBElena Ballarín
Elena Ballarín
MSMònica Sabaté
Mònica Sabaté
JLJoan-Ramon Laporte
Joan-Ramon Laporte
MSMarieke Schoonen
Marieke Schoonen
LILuisa Ibáñez
Luisa Ibáñez

26 December 2015 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
PDF file
PFPili Ferrer
Pili Ferrer
JAJustyna Amelio
Justyna Amelio
EBElena Ballarin
Elena Ballarin
MSMonica Sabate
Monica Sabate
XVXavi Vidal
Xavi Vidal
LILuisa Ibanez
Luisa Ibanez
Antibacterials are frequently associated with idiosyncratic drug‐induced liver injury (DILI). The objective of this study was to estimate the risk of macrolides and amoxicillin/clavulanate (AMC) on DILI. We conducted a systematic review (SR) and meta‐analysis (MA) with studies retrieved from PubMed, Cochrane Library Plus, Web of Knowledge, clinicaltrials.gov, Livertox and Toxline (1980–2014). We searched for macrolides, AMC and MeSH and synonym terms for DILI. We included all study designs except case reports/series, all population ages and studies with a placebo/non‐user comparator. We summarized the evidence with a random‐effects MA. Quality of the studies was appraised with a checklist developed for SR of adverse effects. Heterogeneity and publication bias were assessed with different exploratory tools. We finally included 10 (two randomized clinical trials, six case–control, one cohort and one case–population studies) and 9 (case–population excluded) articles in the SR and MA, respectively. The overall summary relative risk of DILI for macrolides was 2.85 [95% confidence interval (CI) 1.81–4.47], p < 0.0001, I2 = 57%. Three studies were perceived to be missing in the area of low statistical significance. Year of study and selected exposure window partly explained the variability between studies. For AMC, the risk of DILI was 9.38 (95% CI 0.65–135.41) p = 0.3, I2 = 95%. In conclusion, although spontaneous reports and case series have long established an association between macrolides and AMC with acute liver injury, these SR and MA have assessed the magnitude of this association. The low incidence of DILI and the therapeutic place of these antibiotics might tilt the balance in favour of their benefits.

29 December 2014 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
MSMònica Sabaté
Mònica Sabaté
PFPili Ferrer
Pili Ferrer
EBElena Ballarín
Elena Ballarín
MRMarietta Rottenkolber
Marietta Rottenkolber
JAJustyne Amelio
Justyne Amelio
LILuisa Ibáñez
Luisa Ibáñez